Back To Search Instructions
Protocols
10 protocols meet the specified criteria
Disease Site: Prostate
Protocol No.TitleStatus
1410547210Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active SurveillanceOpen
1502660379S1316: Prospective Comparative Effectiveness Trial for Malignant Bowel ObstructionOpen
1603454230ANDROGEN DEPRIVATION THERAPY AND HIGH DOSE RADIOTHERAPY WITH OR WITHOUT WHOLE-PELVIC RADIOTHERAPY IN UNFAVORABLE INTERMEDIATE OR FAVORABLE HIGH RISK PROSTATE CANCER: A PHASE III RANDOMIZED TRIAL Open
1608779834A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced MalignanciesOpen
1612044721A Phase 1 Study of a Prostate-Specific Membrane Antigen Targeting-Tubulysin Conjugate EC1169 in Patients with Recurrent Metastatic, Castration-Resistant, Prostate Cancer (mCRPC)Open
1702219140Bayer 17777: A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancerOpen
1704374063A Phase 1 Open-Label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer SubjectsOpen
PHXA-16-0158-71-15Isolation and Characterization of Circulating Tumor Cells (CTCs)Open
PHXB-11RT007ANDROGEN DEPRIVATION THERAPY AND HIGH DOSE RADIOTHERAPY WITH OR WITHOUT WHOLE-PELVIC RADIOTHERAPY IN UNFAVORABLE INTERMEDIATE OR FAVORABLE HIGH RISK PROSTATE CANCER: A PHASE III RANDOMIZED TRIAL Open
PHXE-15-0038-10-15A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate CancerOpen